Can latanoprost be safely applied to the scalp, or is it only for eyelashes?

Latanoprost is a drug first designed to treat glaucoma, an eye disease that damages the optic nerve due to increased intraocular pressure. Patients prescribed latanoprost eye drops began to notice an unusual side effect: their eyelashes became longer, darker, and thicker. This observation led to interest in prostaglandin analogues for eyelash growth. However, a natural question arises: if latanoprost can influence hair growth around the eye, could it also work — and be tolerated — when applied to the scalp?

Latanoprost is classified as a prostaglandin analogue. Prostaglandins are hormone-like substances that regulate many processes in the body, including blood flow, inflammation, and cellular growth. Hair follicles, like miniature organs, go through repeating cycles of growth (anagen), regression (catagen), and rest (telogen). Published research indicates that prostaglandins influence the duration of these cycles. For example, prolonging the anagen phase can result in longer and denser hair. Latanoprost binds to prostaglandin receptors in hair follicles, potentially altering the cycle to favor active growth.

This mechanism became most visible in eyelashes, and it is the reason a related prostaglandin analogue, bimatoprost (Latisse®), was approved by the FDA in 2008 for cosmetic eyelash growth. Latanoprost itself was not approved for that use; it is approved only as an eye drop to lower eye pressure in glaucoma and ocular hypertension. The scalp is also biologically and structurally different from the eyelid margin. Hair loss on the scalp, particularly androgenetic alopecia, is influenced not only by growth cycles but also by genetic and hormonal factors, especially the action of dihydrotestosterone (DHT). Because of these complexities, the simple transfer of an eyelash treatment to the scalp demands scientific scrutiny.

What the research on scalp application really tells us

The available evidence for latanoprost on the scalp remains limited, and the studies conducted so far are small in scale. Yet they provide some insight into the potential and limitations of this drug.

In 2012, a pilot clinical trial tested latanoprost 0.1% solution in men with androgenetic alopecia. Sixteen men participated in this randomized, double-blind, placebo-controlled study that lasted 24 weeks. Latanoprost was applied once daily to a defined area of the scalp, and changes were evaluated through macrophotography, a technique that captures highly detailed images of scalp hair density. The authors reported an increase in hair density compared with placebo. Although promising, the trial's main weakness was its very small sample size, which makes it difficult to generalize the findings or assess long-term safety, and the 0.1% strength tested is twenty times the 0.005% concentration of the licensed eye drop. The authors themselves concluded that larger studies were required before considering clinical use. (Blume-Peytavi et al., 2012, Journal of the American Academy of Dermatology).

Animal work supports the mechanism. In a murine study, researchers applied prostaglandin F2α and its analogues, latanoprost among them, to shaved mouse skin and reported earlier regrowth and effects on follicular pigment production compared with controls. While this experiment demonstrated a biological mechanism, the criticism lies in the fact that mouse hair cycles differ from human hair cycles. Findings in rodents cannot be directly extrapolated to humans. (Sasaki et al., 2005, Experimental Dermatology).

Beyond the scalp, latanoprost has been reported in a small clinical series on eyelash loss. Coronel-Pérez and colleagues treated eyelash alopecia in patients with alopecia areata universalis and reported regrowth in some of them. That report is about eyelashes in an autoimmune form of hair loss, so it says little about pattern hair loss on the scalp, and we could not verify any published study of latanoprost for eyebrow hypotrichosis. The one scalp trial above remains the only human scalp evidence we could confirm.

Safety concerns when moving beyond eyelashes

Even if latanoprost has shown biological activity on hair follicles, its safety on the scalp remains unverified. Unlike eyelash application, which involves a very small surface area and a low systemic dose, the scalp presents a much larger area for absorption. This raises several critical concerns.

Scalp irritation is one potential problem. Latanoprost may cause redness, itching, or dryness, which could become more pronounced if applied to larger areas. Pigmentation changes are another risk. The eye-drop label states that latanoprost can darken the iris, the eyelid skin and the eyelashes, and that darkening of the iris is likely to be permanent (XALATAN label, section 5.1). A solution applied to the scalp can run or be rubbed into the eyes, so anyone using it near the face should keep it out of the eyes. If used widely on the scalp, skin darkening could also result in uneven skin tones. There is also uncertainty about systemic absorption. Although the ophthalmic dose is small and well characterized, spreading the drug over the scalp might increase the total absorbed amount, with unknown consequences.

There are no human data on latanoprost in pregnancy. The label states that in animal studies, latanoprost given during pregnancy caused malformations, embryo-fetal death and miscarriage at clinically relevant doses (section 8.1). Anyone who is pregnant or trying to conceive should not use it off-label on the scalp without medical advice.

At present, the FDA has approved a prostaglandin analogue for eyelashes — bimatoprost — and none for the scalp. Latanoprost use on the scalp is off-label, meaning it has not been reviewed or approved for that purpose. The available evidence shows biological plausibility, but the absence of large-scale human studies makes it impossible to make any claim about safety or long-term efficacy.

So what does the published record actually support?

One 24-week pilot in 16 men reported higher hair density on a small treated scalp patch (Blume-Peytavi et al. 2012), and a mouse study reported faster regrowth. That is not enough to say whether latanoprost works or is safe on the scalp. These studies are small and preliminary, and they leave important safety questions unanswered. On the evidence available, its use on the scalp is experimental. The critical point is that larger, longer clinical trials are needed before it could be considered a reliable option.

Latanoprost is a prescription eye drop approved only for glaucoma and raised eye pressure, and there is no approved scalp product, no established scalp dose, and no long-term safety data for that use. Talk to a doctor or pharmacist before starting, stopping or combining latanoprost.

References

Blume-Peytavi, U., Lönnfors, S., Hillmann, K., & Garcia Bartels, N. (2012). A randomized double-blind placebo-controlled pilot study to assess the efficacy of a 24-week topical treatment by latanoprost 0.1% on hair growth and pigmentation in healthy volunteers with androgenetic alopecia. Journal of the American Academy of Dermatology, 66(5), 794–800. https://pubmed.ncbi.nlm.nih.gov/21875758/

Coronel-Pérez, I. M., Rodríguez-Rey, E. M., & Camacho-Martínez, F. M. (2010). Latanoprost in the treatment of eyelash alopecia in alopecia areata universalis. Journal of the European Academy of Dermatology and Venereology, 24(4), 481–485. https://pubmed.ncbi.nlm.nih.gov/20028444/

Sasaki, S., Hozumi, Y., & Kondo, S. (2005). Influence of prostaglandin F2α and its analogues on hair regrowth and follicular melanogenesis in a murine model. Experimental Dermatology, 14(5), 323–328. https://pubmed.ncbi.nlm.nih.gov/15854125/

U.S. National Library of Medicine, DailyMed. XALATAN (latanoprost ophthalmic solution) 0.005% — prescribing information (Warnings and Precautions 5.1; Use in Specific Populations 8.1). https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a98595b3-9f47-48e0-b18d-550a2095f264

U.S. Food and Drug Administration. (2008). FDA approves Latisse to treat hypotrichosis of the eyelashes. U.S. Food and Drug Administration. https://www.fda.gov/news-events/press-announcements/fda-approves-latisse-treat-hypotrichosis-eyelashes